Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P60709
UPID:
ACTB_HUMAN
Alternative names:
Beta-actin
Alternative UPACC:
P60709; P02570; P70514; P99021; Q11211; Q64316; Q75MN2; Q96B34; Q96HG5
Background:
Actin, cytoplasmic 1, also known as Beta-actin, is a pivotal protein in cell structure and motility. It exists in monomeric (G-actin) and polymeric (F-actin) forms, essential for cell motility, contraction, and the integrity of the cytoskeleton. Its presence in the nucleus also influences gene transcription and DNA repair. Actin forms the backbone of the ACTR1A/ACTB filament, crucial for the dynactin complex and dynein motor function.
Therapeutic significance:
Actin, cytoplasmic 1, is implicated in juvenile-onset dystonia and Baraitser-Winter syndrome 1, diseases characterized by developmental malformations and neurological symptoms. Understanding the role of Actin, cytoplasmic 1, could open doors to potential therapeutic strategies for these conditions.